www.mhlw.go.jp/stf/houdou/0000073061.html

Latest saved version

抗てんかん薬、双極性障害治療薬「ラミクタール錠」投与患者における重篤な皮膚障害に関する注意喚起について｜厚生労働省

This is the newest public snapshot for this URL and the best place to start reviewing the page.

Source URL

https://www.mhlw.go.jp/stf/houdou/0000073061.html

About this page

This page announces safety warnings from Japan's Ministry of Health, Labour and Welfare regarding "Lamictal tablets," an anti-epileptic and bipolar disorder treatment drug. As of February 4, 2015, four fatal cases of severe skin disorders were reported in patients who received doses exceeding the prescribed dosage. The incidence of skin disorders is significantly higher when dosage instructions are not followed, particularly in children. Healthcare providers are directed to ensure strict adherence to prescribed dosages, recommend early dermatological consultation for rash development, and discontinue medication if symptoms worsen. Patients are advised to immediately consult physicians upon experiencing initial symptoms such as rash or fever.